Goldfrank's toxicologic emergencies / (Record no. 34613)

MARC details
000 -LEADER
fixed length control field 08760pam a2200397 i 4500
001 - CONTROL NUMBER
control field 1719808
003 - CONTROL NUMBER IDENTIFIER
control field TH-BaNU
005 - DATE AND TIME OF LATEST TRANSACTION
control field 20201026131953.0
008 - FIXED-LENGTH DATA ELEMENTS--GENERAL INFORMATION
fixed length control field 201026s2019 nyuac b 001 0 eng
010 ## - LIBRARY OF CONGRESS CONTROL NUMBER
LC control number 2018003226
020 ## - INTERNATIONAL STANDARD BOOK NUMBER
International Standard Book Number 9781259859618 (hardcover)
020 ## - INTERNATIONAL STANDARD BOOK NUMBER
International Standard Book Number 1259859614 (hardcover)
040 ## - CATALOGING SOURCE
Original cataloging agency DNLM
Language of cataloging eng
Description conventions rda
Transcribing agency DNLM
Modifying agency TH-BaNU
041 09 - LANGUAGE CODE
Language code of text/sound track or separate title eng
042 ## - AUTHENTICATION CODE
Authentication code pcc
060 00 - NATIONAL LIBRARY OF MEDICINE CALL NUMBER
Classification number QV 600
Item number N620 2019
245 00 - TITLE STATEMENT
Title Goldfrank's toxicologic emergencies /
Statement of responsibility, etc. [edited by] Lewis S. Nelson, Mary Ann Howland, Neal A. Lewin, Silas W. Smith, Lewis R. Goldfrank, Robert S. Hoffman ; editor emeritus, Neal E. Flomenbaum.
246 1# - VARYING FORM OF TITLE
Title proper/short title Toxicologic emergencies
250 ## - EDITION STATEMENT
Edition statement 11 edition.
264 #1 - PRODUCTION, PUBLICATION, DISTRIBUTION, MANUFACTURE, AND COPYRIGHT NOTICE
Place of production, publication, distribution, manufacture New York :
Name of producer, publisher, distributor, manufacturer McGraw-Hill Education,
Date of production, publication, distribution, manufacture, or copyright notice [2019]
300 ## - PHYSICAL DESCRIPTION
Extent xxvi, 2070 pages :
Other physical details illustraitions, portrait
336 ## - CONTENT TYPE
Content type term text
Source rdacontent
337 ## - MEDIA TYPE
Media type term unmediated
Source rdamedia
338 ## - CARRIER TYPE
Carrier type term volume
Source rdacarrier
504 ## - BIBLIOGRAPHY, ETC. NOTE
Bibliography, etc. note Includes bibliographical references and index.
505 ## - FORMATTED CONTENTS NOTE
Formatted contents note 1. Historical Principles and Perspectives<br/>2. Toxicologic Misfortunes and Catastrophes in History<br/>Part A The General Approach to the Patient<br/>Case Study 1<br/>3. Initial Evaluation of the Patient: Vital Signs and Toxic Syndromes<br/>Case Study 2<br/>4. Principles of Managing the Acutely Poisoned or Overdosed Patient<br/>SC1. Principles of Antidote Stocking<br/>5. Techniques Used to Prevent Gastrointestinal Absorption<br/>SC2. Decontamination Principles: Prevention of Dermal, Ophthalmic, and Inhalational Absorption<br/>A1. Activated Charcoal<br/>A2. Whole-Bowel Irrigation and Other Intestinal Evacuants<br/>6. Principles and Techniques Applied to Enhance Elimination<br/>7. Laboratory Principles<br/>8. Principles of Diagnostic Imaging<br/>9. Pharmacokinetic and Toxicokinetic Principles<br/>Part B The Fundamental Principles of Medical Toxicology<br/>Section I Biochemical and Molecular Concepts<br/>10. Chemical Principles<br/>11. Biochemical and Metabolic Principles<br/>12. Fluid, Electrolyte, and Acid–Base Principles<br/>13. Neurotransmitters and Neuromodulators<br/>14. Withdrawal Principles<br/>Section II Pathophysiologic Basis: Organ Systems<br/>Case Study 3<br/>15. Cardiologic Principles I: Electrophysiologic and Electrocardiographic Principles<br/>16. Cardiologic Principles II: Hemodynamics<br/>Case Study 4<br/>17. Dermatologic Principles<br/>SC3. Transdermal Toxicology<br/>18. Gastrointestinal Principles<br/>19. Genitourinary Principles<br/>20. Hematologic Principles<br/>21. Hepatic Principles<br/>Case Study 5<br/>22. Neurologic Principles<br/>23. Oncologic Principles<br/>24. Ophthalmic Principles<br/>25. Otolaryngologic Principles<br/>26. Psychiatric Principles<br/>SC4. Patient Violence<br/>27. Renal Principles<br/>28. Respiratory Principles<br/>29. Thermoregulatory Principles<br/>Section III Special Populations<br/>30. Reproductive and Perinatal Principles<br/>31. Pediatric Principles<br/>Case Study 6<br/>32. Geriatric Principles<br/>Part C The Clinical Basis of Medical Toxicology<br/>Section I<br/>A. Analgesics and Antiinflammatory Medications<br/>33. Acetaminophen<br/>A3. N-Acetylcysteine<br/>34. Colchicine, Podophyllin, and the Vinca Alkaloids<br/>35. Nonsteroidal Antiinflammatory Drugs<br/>36. Opioids<br/>A4. Opioid Antagonists<br/>SC5. Internal Concealment of Xenobiotics<br/>SC6. Prevention, Treatment, and Harm Reduction Approaches to Opioid Overdoses<br/>37. Salicylates<br/>A5. Sodium Bicarbonate<br/>B. Food, Diet, and Nutrition<br/>38. Botulism<br/>A6. Botulinum Antitoxin<br/>39. Food Poisoning<br/>40. Dieting Xenobiotics and Regimens<br/>41. Athletic Performance Enhancers<br/>42. Essential Oils<br/>43. Plant- and Animal-Derived Dietary Supplements<br/>44. Vitamins<br/>45. Iron<br/>A7. Deferoxamine<br/>C. Pharmaceuticals<br/>46. Pharmaceutical Additives<br/>47. Antidiabetics and Hypoglycemics/Antiglycemics<br/>A8. Dextrose (D-Glucose)<br/>A9. Octreotide<br/>48. Antiepileptics<br/>A10. L-Carnitine<br/>Case Study 7<br/>49. Antihistamines and Decongestants<br/>A11. Physostigmine Salicylate<br/>50. Chemotherapeutics<br/>51. Methotrexate, 5-Fluorouracil, and Capecitabine<br/>A12. Folates: Leucovorin (Folinic Acid) and Folic Acid<br/>A13. Glucarpidase (Carboxypeptidase G2)<br/>A14. Uridine Triacetate<br/>SC7. Intrathecal Administration of Xenobiotics<br/>SC8. Extravasation of Xenobiotics<br/>52. Antimigraine Medications<br/>53. Thyroid and Antithyroid Medications<br/>D. Antimicrobials<br/>54. Antibacterials, Antifungals, and Antivirals<br/>55. Antimalarials<br/>56. Antituberculous Medications<br/>A15. Pyridoxine<br/>E. Cardiopulmonary Medications<br/>57. Antidysrhythmics<br/>A16. Magnesium<br/>58. Antithrombotics<br/>A17. Prothrombin Complex Concentrates and Direct Oral Anticoagulant Antidotes<br/>A18. Vitamin K1<br/>A19. Protamine<br/>Case Study 8<br/>59. β-Adrenergic Antagonists<br/>A20. Glucagon<br/>60. Calcium Channel Blockers<br/>A21. High-Dose Insulin<br/>61. Miscellaneous Antihypertensives and Pharmacologically Related Agents<br/>62. Cardioactive Steroids<br/>A22. Digoxin-Specific Antibody Fragments<br/>63. Methylxanthines and Selective β2-Adrenergic Agonists<br/>F. Anesthetics and Related Medications<br/>64. Local Anesthetics<br/>A23. Lipid Emulsion<br/>65. Inhalational Anesthetics<br/>66. Neuromuscular Blockers<br/>A24. Dantrolene Sodium<br/>G. Psychotropic Medications<br/>67. Antipsychotics<br/>68. Cyclic Antidepressants<br/>69. Serotonin Reuptake Inhibitors and Atypical Antidepressants<br/>70. Lithium<br/>71. Monoamine Oxidase Inhibitors<br/>72. Sedative–Hypnotics<br/>A25. Flumazenil<br/>H. Substances of Abuse<br/>73. Amphetamines<br/>74. Cannabinoids<br/>75. Cocaine<br/>A26. Benzodiazepines<br/>76. Ethanol<br/>A27. Thiamine Hydrochloride<br/>77. Alcohol Withdrawal<br/>78. Disulfiram and Disulfiramlike Reactions<br/>79. Hallucinogens<br/>80. γ-Hydroxybutyric Acid (γ-Hydroxybutyrate)<br/>81. Inhalants<br/>82. Nicotine<br/>83. Phencyclidine and Ketamine<br/>I. Metals<br/>Case Study 9<br/>84. Aluminum<br/>85. Antimony<br/>86. Arsenic<br/>A28. Dimercaprol (British Anti-Lewisite or Bal)<br/>87. Bismuth<br/>88. Cadmium<br/>89. Cesium<br/>90. Chromium<br/>91. Cobalt<br/>92. Copper<br/>93. Lead<br/>A29. Succimer (2,3-Dimercaptosuccinic Acid) and DMPS (2,3-Dimercapto-1-Propanesulfonic Acid)<br/>A30. Edetate Calcium Disodium (CaNa2EDTA)<br/>94. Manganese<br/>95. Mercury<br/>96. Nickel<br/>97. Selenium<br/>98. Silver<br/>99. Thallium<br/>A31. Prussian Blue<br/>100. Zinc<br/>J. Household Products<br/>101. Antiseptics, Disinfectants, and Sterilants<br/>102. Camphor and Moth Repellents<br/>103. Caustics<br/>104. Hydrofluoric Acid and Fluorides<br/>A32. Calcium<br/>105. Hydrocarbons<br/>Case Study 10<br/>106. Toxic Alcohols<br/>A33. Fomepizole<br/>A34. Ethanol<br/>SC9. Diethylene Glycol<br/>K. Pesticides<br/>Case Study 11<br/>107. Barium<br/>108. Fumigants<br/>109. Herbicides<br/>110. Insecticides: Organic Phosphorous Compounds and Carbamates<br/>A35. Atropine<br/>A36. Pralidoxime<br/>111. Insecticides: Organic Chlorines, Pyrethrins/Pyrethroids, and Insect Repellents<br/>112. Phosphorus<br/>113. Sodium Monofluoroacetate and Fluoroacetamide<br/>114. Strychnine<br/>L. Natural Toxins and Envenomations<br/>115. Arthropods<br/>A37. Antivenom: Spider<br/>A38. Antivenom: Scorpion<br/>116. Marine Envenomations<br/>117. Mushrooms<br/>118. Plants<br/>119. Native (US) Venomous Snakes and Lizards<br/>A39. Antivenom for North American Venomous Snakes (Crotaline and Elapid)<br/>SC10. Exotic Nonnative Snake Envenomations<br/>M. Occupational and Environmental Toxins<br/>Case Study 12<br/>120. Smoke Inhalation<br/>Case Study 13<br/>121. Simple Asphyxiants and Pulmonary Irritants<br/>122. Carbon Monoxide<br/>A40. Hyperbaric Oxygen<br/>123. Cyanide and Hydrogen Sulfide<br/>A41. Hydroxocobalamin<br/>A42. Nitrites (Amyl and Sodium) and Sodium Thiosulfate<br/>124. Methemoglobin Inducers<br/>A43. Methylene Blue<br/>125. Nanotoxicology<br/>N. Disaster Preparedness<br/>126. Chemical Weapons<br/>127. Biological Weapons<br/>128. Radiation<br/>A44. Potassium Iodide<br/>A45. Pentetic Acid or Pentetate (Zinc or Calcium) Trisodium (DTPA)<br/>Part D Population Health<br/>Section I Poison Control Centers, Health Systems, and Epidemiology<br/>129. Poison Prevention and Education<br/>130. Poison Control Centers and Poison Epidemiology<br/>131. Principles of Occupational Toxicology: Diagnosis and Control<br/>132. Hazardous Materials Incident Response<br/>133. Risk Assessment and Risk Communication<br/>Case Study 14<br/>134. Medication Safety and Adverse Drug Events<br/>135. Drug Development, Adverse Drug Events, and Postmarketing Surveillance<br/>136. International Perspectives on Medical Toxicology<br/>137. Principles of Epidemiology and Research Design<br/>Section II Legal Aspects of Toxicology<br/>138. Risk Management and Legal Principles<br/>139. Medicolegal Interpretive Toxicology<br/>SC11. Assessment of Ethanol-Induced Impairment<br/>140. Postmortem Toxicology<br/>SC12. Organ Procurement from Poisoned Patients<br/>Index
650 12 - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name entry element Emergencies
Authority record control number or standard number https://id.nlm.nih.gov/mesh/D004630
650 12 - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name entry element Poisoning
Authority record control number or standard number https://id.nlm.nih.gov/mesh/D011041
650 22 - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name entry element Poisons
Authority record control number or standard number https://id.nlm.nih.gov/mesh/D011042
655 #2 - INDEX TERM--GENRE/FORM
Genre/form data or focus term Case Reports
Authority record control number https://id.nlm.nih.gov/mesh/D002363
700 1# - ADDED ENTRY--PERSONAL NAME
Personal name Nelson, Lewis,
Dates associated with a name 1963-
Relator term editor.
850 ## - HOLDING INSTITUTION
Holding institution Kuakarun Nursing Library
942 ## - ADDED ENTRY ELEMENTS (KOHA)
Source of classification or shelving scheme National Library of Medicine Classification
Koha item type General Book
998 ## - STAFF NAME (NMU)
Cataloger nuch
Holdings
Withdrawn status Lost status Source of classification or shelving scheme Damaged status Not for loan Home library Current library Shelving location Date acquired Total Checkouts Full call number Barcode Date last seen Price effective from Koha item type
    National Library of Medicine Classification     Kuakarun Nursing Library Kuakarun Nursing Library Processing unit 26/10/2020   QV 600 N620 2019 0000045395 26/10/2020 26/10/2020 General Book